ECSP088511A - Agonistas del receptor del neuropeptido-2 - Google Patents

Agonistas del receptor del neuropeptido-2

Info

Publication number
ECSP088511A
ECSP088511A EC2008008511A ECSP088511A ECSP088511A EC SP088511 A ECSP088511 A EC SP088511A EC 2008008511 A EC2008008511 A EC 2008008511A EC SP088511 A ECSP088511 A EC SP088511A EC SP088511 A ECSP088511 A EC SP088511A
Authority
EC
Ecuador
Prior art keywords
neuropeptido
agonists
receiver agonists
receiver
neuropeptide
Prior art date
Application number
EC2008008511A
Other languages
English (en)
Inventor
Jefferson Wright Tilley
Nader Fotouhi
Waleed Danho
Joseph Swistok
Karin Conde-Knape
George Ehrlich
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Rebecca Anne Taub
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088511(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP088511A publication Critical patent/ECSP088511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan agonistas del receptor del neuropéptido-2 de fórmula (I): Y' | Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2 (I),así como las sales farmacéuticamente aceptables, derivados y fragmentos del mismo, en el que los sustituyentes son tal y como se describen en la especificación. Estos compuestos, y las composiciones farmacéuticas que los contienen, son útiles para el tratamiento de enfermedades como, por ejemplo, la obesidad y la diabetes.
EC2008008511A 2005-12-07 2008-06-06 Agonistas del receptor del neuropeptido-2 ECSP088511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74807105P 2005-12-07 2005-12-07
US85524906P 2006-10-30 2006-10-30

Publications (1)

Publication Number Publication Date
ECSP088511A true ECSP088511A (es) 2008-07-30

Family

ID=37964711

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008511A ECSP088511A (es) 2005-12-07 2008-06-06 Agonistas del receptor del neuropeptido-2

Country Status (18)

Country Link
US (2) US7642244B2 (es)
EP (1) EP1962959B1 (es)
JP (1) JP5000663B2 (es)
KR (1) KR101059602B1 (es)
AR (1) AR057222A1 (es)
AT (1) ATE549350T1 (es)
AU (1) AU2006324076A1 (es)
BR (1) BRPI0619573A2 (es)
CA (1) CA2630649A1 (es)
EC (1) ECSP088511A (es)
ES (1) ES2381497T3 (es)
IL (1) IL191636A (es)
MA (1) MA30142B1 (es)
NO (1) NO20082445L (es)
NZ (1) NZ568772A (es)
RU (2) RU2430108C2 (es)
TW (1) TWI321474B (es)
WO (1) WO2007065808A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010069242A (ko) * 2000-09-05 2001-07-25 양우용 저주파 물리치료 겸용 혈압 강하기
EP1962959B1 (en) * 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Neuropeptide-2 receptor-agonists
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
BRPI0921230A2 (pt) * 2008-11-05 2018-10-30 Hoffmann La Roche agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo.
EP2450374B9 (en) 2009-07-02 2016-11-23 Takeda Pharmaceutical Company Limited Peptide and use thereof
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
JP2013507414A (ja) * 2009-10-13 2013-03-04 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド−２受容体（ｙ−２ｒ）アゴニスト
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
JP2014502607A (ja) * 2011-01-03 2014-02-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｄｉｇ抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
EP2869837B1 (en) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
SG11201407420RA (en) 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
WO2015071355A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
MX392572B (es) 2015-06-12 2025-03-24 Novo Nordisk As Compuestos del péptido yy (pyy) selectivos y sus usos.
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
KR20220100925A (ko) 2019-11-11 2022-07-18 베링거 인겔하임 인터내셔날 게엠베하 Npy2 수용체 작용제
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CN1124927A (zh) * 1993-03-29 1996-06-19 辛辛那提大学 Yy肽类似物及其应用
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6013633A (en) * 1997-08-07 2000-01-11 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
US7811989B2 (en) * 2003-01-17 2010-10-12 Ipsen Pharma S.A.S. Peptide YY analogs
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US20090105122A1 (en) 2003-11-25 2009-04-23 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
EP1718671A2 (en) 2004-02-23 2006-11-08 Rheoscience A/S Peptide yy analogues
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
EP1962959B1 (en) * 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Neuropeptide-2 receptor-agonists
WO2007085887A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Pyy agonists and uses thereof

Also Published As

Publication number Publication date
NO20082445L (no) 2008-09-03
EP1962959A2 (en) 2008-09-03
WO2007065808A3 (en) 2007-08-02
TWI321474B (en) 2010-03-11
AU2006324076A1 (en) 2007-06-14
RU2430108C2 (ru) 2011-09-27
US7642244B2 (en) 2010-01-05
EP1962959B1 (en) 2012-03-14
RU2008127265A (ru) 2010-01-20
JP5000663B2 (ja) 2012-08-15
RU2011105310A (ru) 2012-08-20
NZ568772A (en) 2010-05-28
US20100137223A1 (en) 2010-06-03
US8268784B2 (en) 2012-09-18
TW200806311A (en) 2008-02-01
MA30142B1 (fr) 2009-01-02
ATE549350T1 (de) 2012-03-15
KR101059602B1 (ko) 2011-08-25
IL191636A (en) 2012-10-31
CA2630649A1 (en) 2007-06-14
IL191636A0 (en) 2008-12-29
AR057222A1 (es) 2007-11-21
WO2007065808A2 (en) 2007-06-14
JP2009518349A (ja) 2009-05-07
ES2381497T3 (es) 2012-05-28
US20070135351A1 (en) 2007-06-14
KR20080082672A (ko) 2008-09-11
BRPI0619573A2 (pt) 2011-10-04

Similar Documents

Publication Publication Date Title
AR057222A1 (es) Agonistas del receptor del neuropeprtido -2
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
ECSP088747A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
CR20110077A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
UY30267A1 (es) Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones
GT200600114A (es) Derivados de ciclopropanocarboxamida
CR10621A (es) Derivados de adenosina como agonistas del receptor a2a
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
ECSP109934A (es) Compuesto - 946
PA8577101A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparacion de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos
ECSP066855A (es) Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen esos compuestos, su aplicación y procedimiento para su preparación
IN2012DN03042A (es)
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
TW200643013A (en) Pyrazoles
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
CR8270A (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas